| Sun, Zimin |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
| Recruiting | 2 | 120 | RoW | Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2, Mecapegfilgrastim, day 5 | Qiu Lugui, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Multiple Myeloma, Lymphoma | 03/24 | 09/24 | | |
NCT04174586: Cord Blood Microtransplantation for Treatment of Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 20 | RoW | microtransplantation | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Safety Issues, Efficiency | 08/24 | 08/24 | | |
| Zeng, Qingshu |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation |
|
|
| Active, not recruiting | 2 | 90 | RoW | Ponatinib, Iclusig, AP24534 | Otsuka Beijing Research Institute | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | 07/22 | 12/25 | | |
NCT05186558: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 54 | RoW | penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin | The First Affiliated Hospital with Nanjing Medical University | Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type | 01/24 | 02/26 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
